Sabby Management’s XTL Biopharmaceuticals XTLB Stock Holding History

Sabby Management’s Portfolio XTLB Stock Details XTLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-36,207	Closed	-$434K	–	322
2016 Q4	$434K	Sell	36,207 -1,357	-4%	-$20.6K	0.03%	204
2016 Q3	$714K	Sell	37,564 -12,495	-25%	-$271K	0.03%	205
2016 Q2	$1.16M	Sell	50,059 -1,951	-4%	-$41.9K	0.06%	153
2016 Q1	$1.07M	Sell	52,010 -3,588	-6%	-$92.1K	0.05%	153
2015 Q4	$1.67M	Sell	55,598 -1,896	-3%	-$63.7K	0.09%	142
2015 Q3	$1.79M	Sell	57,494 -55	-0.1%	-$2.03K	0.07%	170
2015 Q2	$2.21M	Sell	57,549 -8,024	-12%	-$342K	0.08%	157
2015 Q1	$3.02M	Buy	+65,573	New	+$2.87M	0.13%	110

Other funds holding XTLB

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sabby Management's XTLB Position: Q1 2017 in Review

Sabby Management sold out of XTL Biopharmaceuticals (XTLB) in Q1 2017, closing a stake of 36,207 shares — an estimated $434K sold.

Sabby Management first reported a position in XTLB in Q1 2015 and held it in 8 quarters. The position peaked at $3.02M in Q1 2015. 3 funds tracked by Wall St. Rank hold XTLB as of Q1 2017.

Sabby Management reported no remaining XTL Biopharmaceuticals position as of Q1 2017 after selling out during the quarter.
Sabby Management sold 36,207 XTL Biopharmaceuticals shares in Q1 2017, an estimated $434K.
Sabby Management first reported a position in XTL Biopharmaceuticals in Q1 2015 and held it in 8 quarters.
Sabby Management's XTL Biopharmaceuticals position peaked at $3.02M in Q1 2015.
3 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q1 2017.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.